ARAY Stock Falls Despite Positive Data of CyberKnife in Treating BSM
Accuray announces positive study data for its CyberKnife System in treating brainstem metastases.
Looking for a Fast-paced Momentum Stock at a Bargain? Consider Accuray (ARAY)
If you are looking for stocks that have gained strong momentum recently but are still trading at reasonable prices, Accuray (ARAY) could be a great choice. It is one of the several stocks that passed through our 'Fast-Paced Momentum at a Bargain' screen.
Here's Why You Should Add Accuray Stock in Your Portfolio Now
ARAY's solid product demand and revenue growth raise optimism about the stock.
Accuray Q1 Earnings Meet Estimates, Sales Beat, Gross Margin Shrinks
ARAY's first-quarter fiscal 2025 earnings meet estimates. Both the top and bottom lines deteriorate year over year.
Accuray Incorporated (ARAY) Q1 2025 Earnings Call Transcript
Accuray Incorporated (ARAY) Q1 2025 Earnings Call Transcript
Accuray (ARAY) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
The headline numbers for Accuray (ARAY) give insight into how the company performed in the quarter ended September 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Accuray (ARAY) Reports Q1 Loss, Tops Revenue Estimates
Accuray (ARAY) came out with a quarterly loss of $0.04 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.03 per share a year ago.
Here's Why You Should Retain Accuray Stock in Your Portfolio Now
ARAY's solid product demand and revenue growth raise optimism about the stock.
Here's Why You Should Retain Accuray Stock in Your Portfolio Now
ARAY's solid product demand and revenue growth raise optimism about the stock.
ARAY Stock Up Following the Use of SGRT on Cancer Patients in Japan
The latest adoption of Accuray's Radixact System and VitalHold package is likely to improve the care provided to cancer patients and their experience.
Accuray Stock Rises After Helix System Wins CE Mark for Cancer Care
ARAY's Helix system, now CE Mark approved, aims to close global cancer care gaps with cost-effective, high-throughput radiotherapy for underserved regions.
Accuray Remains A Perpetual 'Next Year Is Our Year' Story
Accuray posts a strong end to the fiscal year with 16% revenue growth in FQ4, beating expectations and restoring some confidence for the upcoming year. Management's claim that weaker U.S. sales are a consequence of a weaker capex environment don't fully align with the reported U.S. sales results of other med-tech capital equipment companies. Global opportunities remain promising, especially in China's value-priced linac market, and opportunities in Japan, India, other emerging markets are meaningful.
